The European Commission managing Horizon 2020 – the EU Framework Programme for Research and Innovation –  approved HIL’s Phase-II proposal, at a total budget of €3.3M. The positive funding decision, under Horizon 2020 SME instrument, followed an extensive review process, culminating in an in-person pitch by HIL’s senior leadership team in front of a panel of judges in Brussels a few weeks ago. HIL’s vision, execution capabilities, and international partnerships passed with flying colors all of Horizon 2020’s assessment thresholds for the award criteria – excellence, impact, innovation, quality and efficiency of implementation. The new grant will help HIL further advance the development of its innovative Proton Therapy solutions, towards commercialization.

Horizon 2020 is the biggest EU Research and Innovation program ever, and one of the most competitive. Its aim is to foster breakthroughs, discoveries, and world-firsts by taking great ideas from the lab to the market.

In addition, the Knowledge Transfer group at CERN has initiated a pilot program in collaboration with the Israel Innovation Authority (IIA). The purpose of the programme is to explore how cutting-edge Israeli companies and institutes can embrace specific CERN technology and know-how to fuel their innovation and help drive positive impacts on society. HIL Applied Medical was one of the four companies selected for collaboration with CERN. HIL Applied Medical will focus on the use of CERN expertise in the field of magnets and detectors for the development of ultra-compact, high-performance systems for proton therapy. Proton therapy is among the most advanced, focused and precise forms of radiotherapy.

About HIL Applied Medical

HIL Applied Medical is developing a new class of ultra-compact, high-performance proton therapy systems.

“We apply a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective” , said Sagi Brink-Danan, MSc, MBA, CEO of HIL Applied Medical.

HIL Applied Medical was born out of patented research performed at Prof. Arie Zigler’s physics lab at the Hebrew University of Jerusalem and co-founded by him and Dr. Shmuel Eisenmann. The technology was licensed by Yissum, the university’s Technology Transfer company.

Source  HIL Applied Medical